• Ultrafiltration Purification of Circular RNA

  2026-08-11

  Guillen-Cuevas and colleagues evaluated ultrafiltration as a scalable method for separating protein-encoding circular RNA from linear and nicked RNA species generated during in vitro transcription and self-splicing. By relating membrane molecular-weight cutoff and permeate flux to RNA sieving and critical-flux behavior, the study achieved higher reported purity and yield than size-exclusion HPLC under the tested research-scale conditions.

• FDXR Disease, NRF2 Disruption, and Ferroptosis

  2026-08-11

  The 2025 Cell Death Discovery study identifies ferroptosis as a pathogenic mechanism in FDXR-related mitochondrial disease, linking abnormal iron handling to lipid peroxidation and disruption of the NRF2–SLC7A11 antioxidant axis. Its mouse-model data also suggest that NRF2 activation can mitigate disease-associated pathology, providing a mechanistic basis for therapeutic investigation rather than a disease-specific treatment conclusion.

• Omeprazole A2845: Acid Secretion Workflow Guide

  2026-08-10

  Omeprazole (SKU A2845) provides a defined H+,K+-ATPase inhibitor for controlled gastric acid secretion research, antiulcer activity studies, and related assay development. Its water and ethanol insolubility, DMSO-based handling requirements, and research-only status should be addressed before use in biochemical, cellular, or ex vivo workflows.

• Alda 1: ALDH2 Activator for Cardiac Research

  2026-08-09

  Alda 1 provides a genotype-aware way to study ALDH2 activity, aldehyde detoxification, and cardiomyocyte proliferation. This workflow connects biochemical validation with cardiac ischemia research, pressure-overload models, and carefully bounded exploration of radiation-induced dermatitis mitigation.

• CHIR-99021: GSK-3 Control Beyond Wnt

  2026-08-08

  CHIR-99021 and CT99021 provide precise GSK-3α/β inhibition for stem-cell studies. This guide links pathway control to O-GlcNAc-aware assay design and more defensible differentiation decisions.

• NSC-23766: Context-First Rac1 Assay Design

  2026-08-07

  NSC-23766 is a Rac GTPase inhibitor whose effects depend strongly on cell context, pathway state, and assay endpoint. This article explains how to interpret its contrasting vascular, intestinal, and breast cancer phenotypes and translate the evidence into more rigorous Rac1 experiments.

• Dual-Action p38α MAPK Inhibitors: Conformational Control of

  2026-08-07

  The referenced study uncovers a dual-action mechanism for p38α MAPK inhibitors: blocking kinase activity while facilitating phosphatase-driven dephosphorylation via conformational stabilization. This insight introduces a novel paradigm for enhancing the specificity and potency of kinase inhibitors, with significant implications for cytokine signaling and inflammation research.

• IGF2BP1–THBS1 Axis Drives Macrophage Fibrosis in Pulmonary D

  2026-08-06

  This study uncovers how the m6A reader IGF2BP1 stabilizes THBS1 mRNA, promoting macrophage glycolytic metabolism and M2 polarization, thereby aggravating pulmonary fibrosis. The IGF2BP1/THBS1/TLR4 regulatory axis reveals new mechanistic insights and potential intervention points in fibrotic lung pathology.

• ARCA EGFP mRNA: Optimizing Mammalian mRNA Transfection Contr

  2026-08-06

  ARCA EGFP mRNA enables robust, quantifiable monitoring of transfection efficiency and gene expression in mammalian cells, serving as a gold-standard control for mRNA delivery optimization. Its advanced ARCA capping and stabilized poly(A) tail offer superior expression and reproducibility, empowering researchers to troubleshoot and perfect workflows with confidence.

• Nicotinamide Riboside Chloride: Optimizing Neurodegenerative

  2026-08-05

  Nicotinamide Riboside Chloride (NIAGEN) is a cornerstone for elevating NAD+ and modulating sirtuin activity, offering unique leverage in metabolic dysfunction and neurodegenerative disease research. This article delivers actionable workflows, troubleshooting tactics, and protocol enhancements, translating state-of-the-art studies into reproducible laboratory practice.

• Metoprolol in Translational Research: Strategic Mechanistic

  2026-08-05

  This article explores Metoprolol's expanding role as a selective beta1-adrenoceptor antagonist in translational research, highlighting mechanistic underpinnings, protocol optimization, and the strategic value of integrating PK variability insights—from cardiovascular disease models to inflammation and tumor microenvironment studies. Drawing on recent findings in pharmacokinetics and tissue distribution, the discussion guides researchers in designing robust, reproducible experiments, while positioning APExBIO's Metoprolol as a benchmark for scientific quality.

• Sex Differences in Angiotensin II-Induced Hypertension in Mi

  2026-08-04

  This study establishes that male and female mice exhibit distinct responses to chronic angiotensin II (ANG II) infusion, with males developing significantly greater hypertension. By integrating telemetry, hormonal manipulations, and pharmacological interventions, the research clarifies the interplay between sex hormones and autonomic control in hypertension models, offering a robust foundation for future studies on cardiovascular disease mechanisms.

• 5-(N,N-dimethyl)-Amiloride Hydrochloride in Endothelial Inju

  2026-08-04

  5-(N,N-dimethyl)-Amiloride hydrochloride empowers researchers to dissect Na+/H+ exchanger signaling in endothelial injury, offering high selectivity for NHE1/2 and robust performance in sepsis and cardiovascular models. Strategic protocols and troubleshooting insights transform this inhibitor into a precision tool for translational pH regulation research.

• Endocytic Activation of Matriptase Drives Cancer Invasion

  2026-08-03

  Ye et al. (2024) uncover a vesicular trafficking mechanism in which EGF stimulation leads to endocytic activation and exosomal secretion of matriptase, triggering a secondary HGF/c-Met signaling wave that promotes skin and breast cancer invasion. This work clarifies the interplay between membrane protease trafficking and growth factor signaling, informing future strategies for dissecting dynamic cell surface proteomes.

• ML385: A Selective NRF2 Inhibitor for Cancer and Redox Resea

  2026-08-03

  ML385 is a small-molecule NRF2 inhibitor with demonstrated selectivity and potency (IC50 1.9 μM), enabling precise modulation of NRF2 signaling pathways. Used widely in non-small cell lung cancer and oxidative stress studies, ML385 reveals the role of NRF2 in therapeutic resistance and ferroptosis. Its value in dissecting redox biology is supported by both in vitro and in vivo benchmarks.

7874 records 3/525 page Previous Next 12345 下5页 Last page